Polycystic Kidney Disease, Adult

Nephrology

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	OZEMPIC (semaglutide)	Novo Nordisk	$9.2B	25%	Peak	Stable	12.4yr
2	JARDIANCE (empagliflozin)	Boehringer Ingelheim	$8.8B	24%	Peak	Stable	8.6yr
3	TRULICITY (dulaglutide)	Eli Lilly and Company	$7.4B	20%	Peak	Stable
4	FARXIGA (dapagliflozin)	AstraZeneca	$4.3B	12%	Peak	Stable	15.4yr

#1OZEMPIC

$9.2B

Novo Nordisk·Peak12.4yr

#2JARDIANCE

$8.8B

Boehringer Ingelheim·Peak8.6yr

#3TRULICITY

$7.4B

Eli Lilly and Company·Peak

#4FARXIGA

$4.3B

AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists

$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors

$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)

$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists

$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors

$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124

Open Roles

Companies Hiring

Departments

Top Hiring Companies

Vertex Pharmaceuticals

By Department

Commercial(47%)

$108K

Medical Affairs(10%)

$330K

Clinical Excellence(6%)

$140K

Quality Assurance(4%)

$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Centessa PharmaceuticalsMA - Boston

2 programs

LixivaptanPHASE_31 trial

Active Trials

NCT04152837Terminated7Est. Jul 2022

NCT05208866Terminated1Est. Jul 2022

Colorado TherapeuticsCO - Louisville

1 program

Aminohippurate Sodium Inj 20%N/A1 trial

Active Trials

NCT04407481Completed22Est. Oct 2022

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Centessa PharmaceuticalsLixivaptan

Colorado TherapeuticsAminohippurate Sodium Inj 20%

Clinical Trials (3)

Total enrollment: 30 patients across 3 trials

NCT05208866 Centessa PharmaceuticalsLixivaptan

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Start: Feb 2022Est. completion: Jul 20221 patients

Phase 3Terminated

NCT04152837 Centessa PharmaceuticalsLixivaptan

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Start: Sep 2020Est. completion: Jul 20227 patients

Phase 3Terminated

NCT04407481 Colorado TherapeuticsAminohippurate Sodium Inj 20%

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

Start: Nov 2020Est. completion: Oct 202222 patients

N/ACompleted

Related Jobs in Nephrology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Chronic Kidney Disease(220)End Stage Renal Disease(203)Renal Impairment(142)Kidney Transplantation(136)Chronic Kidney Diseases(71)Renal Insufficiency(66)Acute Kidney Injury(66)Kidney Diseases(46)Renal Transplantation(45)Kidney Transplant(41)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.